BofA lowered the firm’s price target on Ultragenyx (RARE) to $74 from $79 and keeps a Buy rating on the shares. The firm adjusted targets among its small-to-mid cap biotech coverage as part of a Q3 earnings preview for the group.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RARE:
- Ultragenyx placed on ‘Positive Catalyst Watch’ at JPMorgan
- Ultragenyx appoints Eric Olson Chief Business Officer
- Ultragenyx Pharmaceutical: Promising Phase 3 Results for DTX401 Reinforce Buy Rating
- Ultragenyx Pharmaceuticals: Strong Buy Rating Backed by Promising Osteogenesis Imperfecta Program and Strategic Developments
- Ultragenyx’s DTX401: Promising Phase 3 Results and Commercial Viability Support Buy Rating